{
    "root": "2f823592-a15f-6f0e-e063-6294a90a6c53",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Diclofenac Sodium and Misoprostol",
    "value": "20250312",
    "ingredients": [
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "CROSPOVIDONE",
            "code": "2S7830E561"
        },
        {
            "name": "HYDROGENATED CASTOR OIL",
            "code": "ZF94AP8MEY"
        },
        {
            "name": "HYPROMELLOSES",
            "code": "3NXW29V3WO"
        },
        {
            "name": "LACTOSE MONOHYDRATE",
            "code": "EWQ57Q8I5X"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "METHACRYLIC ACID AND ETHYL ACRYLATE COPOLYMER",
            "code": "NX76LV5T8J"
        },
        {
            "name": "CELLULOSE, MICROCRYSTALLINE",
            "code": "OP1R32D61U"
        },
        {
            "name": "POVIDONE K30",
            "code": "U725QWY32X"
        },
        {
            "name": "SODIUM HYDROXIDE",
            "code": "55X04QC32I"
        },
        {
            "name": "STARCH, CORN",
            "code": "O8232NY3SJ"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "TRIETHYL CITRATE",
            "code": "8Z96QXD6UM"
        },
        {
            "name": "DICLOFENAC SODIUM",
            "code": "QTG126297Q"
        },
        {
            "name": "MISOPROSTOL",
            "code": "0E43V0BB57"
        }
    ],
    "indications": "diclofenac sodium misoprostol delayed-release tablets indicated treatment signs symptoms osteoarthritis rheumatoid arthritis adult patients high risk developing nsaid-induced gastric duodenal ulcers complications . list factors may increase risk nsaid-induced gastric duodenal ulcers complications [ ( 5.3 ) ] .",
    "contraindications": "lowest effective shortest duration consistent individual patient treatment goals . ( 2.1 ) osteoarthritis : recommended maximal gi protection one tablet ( containing 50 mg diclofenac 0.2 mg misoprostol ) three times daily . diclofenac higher 150 mg/day recommended . ( 2.2 ) rheumatoid arthritis : recommended maximal gi protection one tablet ( containing 50 mg diclofenac 0.2 mg misoprostol ) three four times daily . diclofenac higher 200 mg/day recommended . ( 2.3 ) modifications due intolerance , full prescribing information . ( 2.2 , 2.3 )",
    "warningsAndPrecautions": "diclofenac sodium misoprostol delayed-release tablets , usp supplied : 50 mg/0.2 mg strength white white , round , biconvex tablets , plain one side debossed “ 0397 ” side . 75 mg/0.2 mg strength white white , round , biconvex tablets , plain one side debossed “ 0398 ” side . strengths supplied : strength ndc number size 50 mg/0.2 mg 68001-231-06 bottle 60 75 mg/0.2 mg 68001-232-06 bottle 60 store 20° 25°c ( 68° 77°f ) ; excursions permitted 15° 30°c ( 59° 86°f ) [ usp controlled room temperature ] .",
    "adverseReactions": "diclofenac sodium misoprostol delayed-release tablets contraindicated following patients : pregnancy . misoprostol , component diclofenac sodium misoprostol delayed-release tablets , pregnancy result maternal fetal harm , including uterine rupture , abortion , premature birth , birth defects [ ( 5.1 ) ( 8.1 ) ] setting coronary artery bypass graft ( cabg ) surgery [ ( 5.2 ) ] active gastrointestinal bleeding [ ( 5.3 ) ] history asthma , urticaria , allergic-type taking aspirin nsaids . severe , sometimes fatal , anaphylactic nsaids reported patients [ ( 5.8 , 5.9 ) ] known hypersensitivity ( e.g . , anaphylactic serious skin ) diclofenac sodium misoprostol , prostaglandins , components product [ ( 5.8 , 5.10 ) ]",
    "indications_original": "Diclofenac sodium and misoprostol delayed-release tablets are indicated for treatment of the signs and symptoms of osteoarthritis or rheumatoid arthritis in adult patients at high risk of developing NSAID-induced gastric and duodenal ulcers and their complications. For a list of factors that may increase the risk of NSAID-induced gastric and duodenal ulcers and their complications \n  [see \n   Warnings and Precautions (5.3)].",
    "contraindications_original": "Use the lowest effective dosage for the shortest duration consistent with individual patient treatment goals. ( 2.1 ) Osteoarthritis: The recommended dosage for maximal GI protection is one tablet (containing 50 mg of diclofenac and 0.2 mg of misoprostol) three times daily. A dosage of diclofenac higher than 150 mg/day is not recommended. ( 2.2 ) Rheumatoid Arthritis: The recommended dosage for maximal GI protection is one tablet (containing 50 mg of diclofenac and 0.2 mg of misoprostol) three or four times daily. A dosage of diclofenac higher than 200 mg/day is not recommended. ( 2.3 ) For dosage modifications due to intolerance, see the full Prescribing Information. ( 2.2 , 2.3 )",
    "warningsAndPrecautions_original": "Diclofenac sodium and misoprostol delayed-release tablets, USP are supplied as:\n                  \n                     The 50 mg/0.2 mg dosage strength is white to off white, round, biconvex tablets, plain on one side and debossed with “ \n   0397” on the other side.\n  \n                     The 75 mg/0.2 mg dosage strength is white to off white, round, biconvex tablets, plain on one side and debossed with “ \n   0398” on the other side.\n  \n                  \n                  The dosage strengths are supplied in:\n                  \n                     \n                        \n                        \n                        \n                     \n                     \n                        \n                           \n                              \n                                 \n                                    Strength\n                                 \n                              \n                           \n                           \n                              \n                                 \n                                    NDC Number\n                                 \n                              \n                           \n                           \n                              \n                                 \n                                    Size\n                                 \n                              \n                           \n                        \n                        \n                           \n                              50 mg/0.2 mg\n                           \n                           \n                               68001-231-06\n                           \n                           \n                               bottle of 60\n                           \n                        \n                        \n                           \n                           \n                           \n                        \n                        \n                           \n                           \n                              \n                           \n                           \n                              \n                           \n                        \n                        \n                           \n                              75 mg/0.2 mg\n                           \n                           \n                               68001-232-06\n                           \n                           \n                               bottle of 60\n                           \n                        \n                     \n                  \n                  Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature].",
    "adverseReactions_original": "Diclofenac sodium and misoprostol delayed-Release tablets are contraindicated in the following patients:\n                  \n                     Pregnancy. Use of misoprostol, a component of diclofenac sodium and misoprostol delayed-release tablets, during pregnancy can result in maternal and fetal harm, including uterine rupture, abortion, premature birth, or birth defects \n   [see \n    Warnings and Precautions (5.1) and \n    Use in Specific Populations (8.1)] \n   \n                     \n                     In the setting of coronary artery bypass graft (CABG) surgery \n   [see \n    Warnings and Precautions (5.2)] \n   \n                     \n                     Active gastrointestinal bleeding \n   [see \n    Warnings and Precautions (5.3)] \n   \n                     \n                     History of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs. Severe, sometimes fatal, anaphylactic reactions to NSAIDs have been reported in such patients \n   [see \n                        Warnings and Precautions\n                         ( \n    5.8, \n    5.9)] \n   \n                     \n                     Known hypersensitivity (e.g., anaphylactic reactions and serious skin reactions) to diclofenac sodium and misoprostol, other prostaglandins, or any components of the drug product \n   [see \n    Warnings and Precautions ( \n    5.8, \n    5.10)]"
}